JPWO2020091036A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020091036A5 JPWO2020091036A5 JP2020554977A JP2020554977A JPWO2020091036A5 JP WO2020091036 A5 JPWO2020091036 A5 JP WO2020091036A5 JP 2020554977 A JP2020554977 A JP 2020554977A JP 2020554977 A JP2020554977 A JP 2020554977A JP WO2020091036 A5 JPWO2020091036 A5 JP WO2020091036A5
- Authority
- JP
- Japan
- Prior art keywords
- edaravone
- suspension
- dispersant
- humans
- suspension according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000725 suspension Substances 0.000 claims description 24
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 claims description 21
- 229950009041 edaravone Drugs 0.000 claims description 21
- 239000002270 dispersing agent Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 3
- 229920000609 methyl cellulose Polymers 0.000 claims 3
- 239000001923 methylcellulose Substances 0.000 claims 3
- 239000000375 suspending agent Substances 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 229960003943 hypromellose Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- -1 sucrose fatty acid ester Chemical class 0.000 claims 2
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- 229920001615 Tragacanth Polymers 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000007922 dissolution test Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000007127 saponification reaction Methods 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 239000000196 tragacanth Substances 0.000 claims 1
- 235000010487 tragacanth Nutrition 0.000 claims 1
- 229940116362 tragacanth Drugs 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023075654A JP7828317B2 (ja) | 2018-11-02 | 2023-05-01 | 経口投与用エダラボン懸濁剤 |
| JP2025168147A JP2026010001A (ja) | 2018-11-02 | 2025-10-06 | 経口投与用エダラボン懸濁剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018207646 | 2018-11-02 | ||
| JP2018207646 | 2018-11-02 | ||
| PCT/JP2019/043013 WO2020091036A1 (ja) | 2018-11-02 | 2019-11-01 | 経口投与用エダラボン懸濁剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023075654A Division JP7828317B2 (ja) | 2018-11-02 | 2023-05-01 | 経口投与用エダラボン懸濁剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020091036A1 JPWO2020091036A1 (ja) | 2021-09-24 |
| JPWO2020091036A5 true JPWO2020091036A5 (cg-RX-API-DMAC7.html) | 2022-11-09 |
| JP7274502B2 JP7274502B2 (ja) | 2023-05-16 |
Family
ID=70463399
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554977A Active JP7274502B2 (ja) | 2018-11-02 | 2019-11-01 | 経口投与用エダラボン懸濁剤 |
| JP2023075654A Active JP7828317B2 (ja) | 2018-11-02 | 2023-05-01 | 経口投与用エダラボン懸濁剤 |
| JP2025168147A Pending JP2026010001A (ja) | 2018-11-02 | 2025-10-06 | 経口投与用エダラボン懸濁剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023075654A Active JP7828317B2 (ja) | 2018-11-02 | 2023-05-01 | 経口投与用エダラボン懸濁剤 |
| JP2025168147A Pending JP2026010001A (ja) | 2018-11-02 | 2025-10-06 | 経口投与用エダラボン懸濁剤 |
Country Status (20)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019167178A1 (ja) * | 2018-02-28 | 2019-09-06 | 田辺三菱製薬株式会社 | 3-メチル-1-フェニル-2-ピラゾリン-5-オン原薬の分析方法、筋萎縮性側索硬化症の治療および筋萎縮性側索硬化症の進行抑制、ならびに、3-メチル-1-フェニル-2-ピラゾリン-5-オン原薬を含む薬剤の製造方法 |
| BR112021008197A2 (pt) | 2018-11-02 | 2021-08-03 | Mitsubishi Tanabe Pharma Corporation | suspensão de edaravone para administração oral |
| US11826352B2 (en) | 2018-11-02 | 2023-11-28 | Mitsubishi Tanabe Pharma Corporation | Edaravone suspension for oral administration |
| IN201921028874A (cg-RX-API-DMAC7.html) * | 2019-07-18 | 2021-01-22 | ||
| JPWO2022102737A1 (cg-RX-API-DMAC7.html) | 2020-11-12 | 2022-05-19 | ||
| US12194025B2 (en) | 2020-11-12 | 2025-01-14 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical composition for oral administration of edaravone and method of administering same |
| GB202103807D0 (en) | 2021-03-18 | 2021-05-05 | Johnson Matthey Plc | A crystalline salt of edaravone, processes for the preparation and use thereof |
| EP4473965A4 (en) | 2022-02-03 | 2026-01-07 | Mitsubishi Tanabe Pharma Corp | MEDICAL AGENT FOR THE TREATMENT OR SUPPRESSION OF THE PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS |
| WO2024005187A1 (ja) | 2022-07-01 | 2024-01-04 | 田辺三菱製薬株式会社 | 組成物、およびエダラボンの応答可能性の評価方法 |
| WO2024172852A1 (en) | 2023-02-16 | 2024-08-22 | Slayback Pharma Llc | Stable pharmaceutical compositions of edaravone |
| CN118178328A (zh) * | 2024-03-21 | 2024-06-14 | 药云(西安)医药技术有限公司 | 依达拉奉包埋物制备方法与其口服制剂 |
| US20260130849A1 (en) * | 2024-11-13 | 2026-05-14 | Tulex Pharmaceuticals, Inc. | Edaravone Oral Solution Compositions |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61263917A (ja) | 1985-05-20 | 1986-11-21 | Mitsubishi Yuka Yakuhin Kk | 脳機能正常化剤 |
| JPH07121861B2 (ja) | 1986-11-25 | 1995-12-25 | 三菱化学株式会社 | 3−メチル−1−フエニル−2−ピラゾロン−5−オンを含有する安定な注射剤 |
| JPH0531523A (ja) | 1991-07-26 | 1993-02-09 | Aichi Steel Works Ltd | ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置 |
| JP3402195B2 (ja) * | 1997-05-14 | 2003-04-28 | 千寿製薬株式会社 | 再分散性の良い水性懸濁液剤 |
| JPH1120463A (ja) | 1997-06-30 | 1999-01-26 | Zexel Corp | 車両用デュアルエアコン |
| ES2248144T3 (es) | 2000-10-24 | 2006-03-16 | Mitsubishi Pharma Corporation | Medicamentos para tratar la esclerosis lateral amiotrofica (ela). |
| JP2004091441A (ja) * | 2002-09-04 | 2004-03-25 | Mitsubishi Pharma Corp | ピラゾロン誘導体を含有する経口投与製剤 |
| EP1714960B1 (en) | 2004-02-09 | 2018-03-28 | Mitsubishi Tanabe Pharma Corporation | Novel therapeutic agent for amyotrophic lateral sclerosis (als) or disease attributable to als |
| JP5836004B2 (ja) | 2010-08-12 | 2015-12-24 | 日新化成株式会社 | 可溶化剤 |
| CN102824356A (zh) | 2012-09-25 | 2012-12-19 | 江西中医学院 | 一种黄芩苷纳晶混悬剂、纳晶干粉及其制备方法 |
| US9642843B2 (en) | 2013-02-27 | 2017-05-09 | The Regents Of The University Of Michigan | Pharmaceutical compounds and use of same in cancer and tauopathies |
| JP6336246B2 (ja) * | 2013-03-13 | 2018-06-06 | 大同化成工業株式会社 | ナノ粒子化製剤及びその製造方法 |
| CN105878171A (zh) * | 2014-12-22 | 2016-08-24 | 南京海恒医药科技有限公司 | 一种依达拉奉新制剂及其制备方法 |
| CN107205935A (zh) | 2015-01-20 | 2017-09-26 | 默克专利股份有限公司 | 用聚乙烯醇作载体聚合物的化合物固体分散体 |
| EP3427724A4 (en) | 2016-03-10 | 2019-11-13 | Sumitomo Dainippon Pharma Co., Ltd. | COMPOSITION WITH FINE PARTICLES AND METHOD FOR THE MANUFACTURE THEREOF |
| CN109125261B (zh) * | 2016-03-16 | 2021-11-30 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
| EP3785703A1 (en) | 2017-01-17 | 2021-03-03 | Treeway TW001 B.V. | Treatment comprising oral or gastric administration of edaravone |
| BR112019014712A2 (pt) * | 2017-01-17 | 2020-02-18 | Treeway Tw001 B.V. | Tratamento médio que compreende a administração entérica de edaravona |
| KR20200024868A (ko) * | 2017-07-06 | 2020-03-09 | 트리웨이 티더블유001 비.브이. | 산화성 스트레스-매개 신경퇴행성 질환의 경구 치료에 사용하기 위한 에다라본의 용도 |
| BR112021008197A2 (pt) * | 2018-11-02 | 2021-08-03 | Mitsubishi Tanabe Pharma Corporation | suspensão de edaravone para administração oral |
| IN201921028874A (cg-RX-API-DMAC7.html) * | 2019-07-18 | 2021-01-22 |
-
2019
- 2019-11-01 BR BR112021008197-6A patent/BR112021008197A2/pt unknown
- 2019-11-01 PT PT198807703T patent/PT3875085T/pt unknown
- 2019-11-01 KR KR1020217016462A patent/KR20210087490A/ko active Pending
- 2019-11-01 AU AU2019369843A patent/AU2019369843A1/en not_active Abandoned
- 2019-11-01 CN CN202311552338.3A patent/CN117379369A/zh active Pending
- 2019-11-01 CN CN202311552339.8A patent/CN117379370A/zh active Pending
- 2019-11-01 WO PCT/JP2019/043013 patent/WO2020091036A1/ja not_active Ceased
- 2019-11-01 IL IL319280A patent/IL319280A/en unknown
- 2019-11-01 AR ARP190103206A patent/AR116967A1/es unknown
- 2019-11-01 EP EP19880770.3A patent/EP3875085B1/en active Active
- 2019-11-01 HU HUE19880770A patent/HUE068117T2/hu unknown
- 2019-11-01 ES ES19880770T patent/ES2991523T3/es active Active
- 2019-11-01 CN CN202311552337.9A patent/CN117398346A/zh active Pending
- 2019-11-01 SG SG11202104365QA patent/SG11202104365QA/en unknown
- 2019-11-01 JP JP2020554977A patent/JP7274502B2/ja active Active
- 2019-11-01 CN CN201980072370.7A patent/CN112969459B/zh active Active
- 2019-11-01 EP EP24181935.8A patent/EP4420724A3/en active Pending
- 2019-11-01 IL IL282773A patent/IL282773B2/en unknown
- 2019-11-01 MX MX2021005144A patent/MX2021005144A/es unknown
- 2019-11-01 FI FIEP19880770.3T patent/FI3875085T3/fi active
- 2019-11-01 PL PL19880770.3T patent/PL3875085T3/pl unknown
- 2019-11-01 TW TW108139797A patent/TWI924629B/zh active
- 2019-11-01 DK DK19880770.3T patent/DK3875085T3/da active
-
2020
- 2020-05-12 US US16/872,741 patent/US10987341B2/en active Active
-
2021
- 2021-03-26 US US17/213,501 patent/US11241416B2/en active Active
- 2021-04-30 PH PH12021550988A patent/PH12021550988A1/en unknown
- 2021-04-30 MX MX2023009973A patent/MX2023009973A/es unknown
- 2021-04-30 MX MX2024000663A patent/MX2024000663A/es unknown
- 2021-12-23 US US17/560,493 patent/US11478450B2/en active Active
-
2022
- 2022-09-22 US US17/934,234 patent/US11957660B2/en active Active
-
2023
- 2023-05-01 JP JP2023075654A patent/JP7828317B2/ja active Active
-
2024
- 2024-03-26 US US18/616,227 patent/US12599586B2/en active Active
-
2025
- 2025-07-21 AU AU2025205635A patent/AU2025205635A1/en active Pending
- 2025-10-06 JP JP2025168147A patent/JP2026010001A/ja active Pending
-
2026
- 2026-04-13 US US19/646,107 patent/US20260232635A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026010001A5 (cg-RX-API-DMAC7.html) | ||
| JP5607083B2 (ja) | リルゾール水性懸濁液 | |
| JP6449205B2 (ja) | ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物 | |
| JP2016503762A5 (cg-RX-API-DMAC7.html) | ||
| RU2011145278A (ru) | Композиции клозапина с контролируемым высвобождением | |
| JP2004503484A (ja) | 多孔質セレコキシブマトリックスおよびその製造方法 | |
| TW201023912A (en) | Pharmaceutical suspension | |
| JP2021169504A (ja) | アプレピタント経口液体製剤 | |
| JP2021169510A5 (cg-RX-API-DMAC7.html) | ||
| JP2016513625A5 (cg-RX-API-DMAC7.html) | ||
| EA027720B1 (ru) | Способ получения пленки, содержащей свободное основание силденафила | |
| HK1046366A1 (en) | Ziprasidone suspension | |
| ES2553107T3 (es) | Composición anti-inflamatoria basada en compuestos de estroncio | |
| EP0594770B1 (fr) | Compositions ophtalmiques a base d'oxicam ou de derives d'oxicam | |
| CN1642537A (zh) | 用于硬壳胶囊的布洛芬溶液 | |
| WO2006132342A1 (ja) | ロフルミラスト点眼液 | |
| JPWO2008099615A1 (ja) | 微粒子油性懸濁液を含む医薬組成物 | |
| KR20090098610A (ko) | 입자크기가 조절된 술포데히드로아비에트산을 함유한쓴맛이 저감된 경구용 액상 조성물 | |
| WO1997041864A1 (en) | Ophthalmic preparations | |
| JP5922609B2 (ja) | 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性組成物 | |
| CN102482316A (zh) | 熊去氧胆酸-合成水滑石-丙烯酸树脂杂合体、包含该杂合体的药物组合物及其制备方法 | |
| KR102778468B1 (ko) | 저점도 점안 조성물의 제조방법 | |
| RU2021115473A (ru) | Суспензия эдаравона для перорального введения | |
| KR970001712B1 (ko) | 개선된 저점도의 고농도 황산바륨 조영제 및 그의 제조방법 | |
| JPH05186348A (ja) | 水性懸濁液剤の製造法 |